vs
Side-by-side financial comparison of Bausch & Lomb Corp (BLCO) and Warby Parker Inc. (WRBY). Click either name above to swap in a different company.
Bausch & Lomb Corp is the larger business by last-quarter revenue ($1.4B vs $212.0M, roughly 6.6× Warby Parker Inc.). Warby Parker Inc. runs the higher net margin — -2.8% vs -4.1%, a 1.3% gap on every dollar of revenue. On growth, Warby Parker Inc. posted the faster year-over-year revenue change (11.2% vs 9.8%). Bausch & Lomb Corp produced more free cash flow last quarter ($60.0M vs $8.1M). Over the past eight quarters, Bausch & Lomb Corp's revenue compounded faster (13.1% CAGR vs 2.9%).
Bausch & Lomb is an American-Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company was founded in Rochester, New York, in 1853 by optician John Bausch and cabinet maker turned financial backer Henry Lomb. Until its sale in 2013, Bausch + Lomb was one of the oldest continually operating companies in the United States.
Warby Parker Inc. is an American eyewear brand and retailer of prescription glasses, contact lenses, and sunglasses, based in New York City. It also offers eye exams. Originally founded in 2010 as an online-only retailer, the company now generates about two-thirds of its revenue from its 276 physical retail stores, 271 of which are in the U.S. and 5 of which are in Canada. The company intends to operate 900 stores. The company has 2.28 million customers; average order value is $263.
BLCO vs WRBY — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $212.0M |
| Net Profit | $-58.0M | $-6.0M |
| Gross Margin | — | 52.4% |
| Operating Margin | 8.0% | -3.2% |
| Net Margin | -4.1% | -2.8% |
| Revenue YoY | 9.8% | 11.2% |
| Net Profit YoY | -1833.3% | 13.4% |
| EPS (diluted) | $-0.16 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.4B | $212.0M | ||
| Q3 25 | $1.3B | $221.7M | ||
| Q2 25 | $1.3B | $214.5M | ||
| Q1 25 | $1.1B | $223.8M | ||
| Q4 24 | $1.3B | $190.6M | ||
| Q3 24 | $1.2B | $192.4M | ||
| Q2 24 | $1.2B | $188.2M | ||
| Q1 24 | $1.1B | $200.0M |
| Q4 25 | $-58.0M | $-6.0M | ||
| Q3 25 | $-28.0M | $5.9M | ||
| Q2 25 | $-62.0M | $-1.8M | ||
| Q1 25 | $-212.0M | $3.5M | ||
| Q4 24 | $-3.0M | $-6.9M | ||
| Q3 24 | $4.0M | $-4.1M | ||
| Q2 24 | $-151.0M | $-6.8M | ||
| Q1 24 | $-167.0M | $-2.7M |
| Q4 25 | — | 52.4% | ||
| Q3 25 | — | 54.1% | ||
| Q2 25 | — | 53.0% | ||
| Q1 25 | — | 56.3% | ||
| Q4 24 | — | 54.1% | ||
| Q3 24 | — | 54.5% | ||
| Q2 24 | — | 56.0% | ||
| Q1 24 | — | 56.7% |
| Q4 25 | 8.0% | -3.2% | ||
| Q3 25 | 7.4% | 1.6% | ||
| Q2 25 | -0.9% | -2.1% | ||
| Q1 25 | -7.3% | 1.1% | ||
| Q4 24 | 6.8% | -4.9% | ||
| Q3 24 | 3.6% | -3.4% | ||
| Q2 24 | 2.1% | -4.8% | ||
| Q1 24 | 0.5% | -2.6% |
| Q4 25 | -4.1% | -2.8% | ||
| Q3 25 | -2.2% | 2.6% | ||
| Q2 25 | -4.9% | -0.8% | ||
| Q1 25 | -18.6% | 1.6% | ||
| Q4 24 | -0.2% | -3.6% | ||
| Q3 24 | 0.3% | -2.1% | ||
| Q2 24 | -12.4% | -3.6% | ||
| Q1 24 | -15.2% | -1.3% |
| Q4 25 | $-0.16 | $-0.06 | ||
| Q3 25 | $-0.08 | $0.05 | ||
| Q2 25 | $-0.18 | $-0.01 | ||
| Q1 25 | $-0.60 | $0.03 | ||
| Q4 24 | $-0.00 | $-0.06 | ||
| Q3 24 | $0.01 | $-0.03 | ||
| Q2 24 | $-0.43 | $-0.06 | ||
| Q1 24 | $-0.48 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $383.0M | $286.4M |
| Total DebtLower is stronger | $5.0B | — |
| Stockholders' EquityBook value | $6.4B | $367.7M |
| Total Assets | $14.0B | $720.9M |
| Debt / EquityLower = less leverage | 0.78× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $383.0M | $286.4M | ||
| Q3 25 | $310.0M | $280.4M | ||
| Q2 25 | $266.0M | $286.4M | ||
| Q1 25 | $202.0M | $265.1M | ||
| Q4 24 | $305.0M | $254.2M | ||
| Q3 24 | $329.0M | $251.0M | ||
| Q2 24 | $285.0M | $238.0M | ||
| Q1 24 | $315.0M | $220.4M |
| Q4 25 | $5.0B | — | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $4.8B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — | ||
| Q1 24 | $4.6B | — |
| Q4 25 | $6.4B | $367.7M | ||
| Q3 25 | $6.4B | $369.6M | ||
| Q2 25 | $6.4B | $361.5M | ||
| Q1 25 | $6.4B | $354.1M | ||
| Q4 24 | $6.5B | $340.1M | ||
| Q3 24 | $6.6B | $336.8M | ||
| Q2 24 | $6.5B | $329.4M | ||
| Q1 24 | $6.7B | $316.2M |
| Q4 25 | $14.0B | $720.9M | ||
| Q3 25 | $13.8B | $706.9M | ||
| Q2 25 | $13.8B | $701.9M | ||
| Q1 25 | $13.4B | $682.8M | ||
| Q4 24 | $13.5B | $676.5M | ||
| Q3 24 | $13.5B | $638.0M | ||
| Q2 24 | $13.3B | $618.2M | ||
| Q1 24 | $13.3B | $592.9M |
| Q4 25 | 0.78× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.76× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 0.69× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $136.0M | $23.3M |
| Free Cash FlowOCF − Capex | $60.0M | $8.1M |
| FCF MarginFCF / Revenue | 4.3% | 3.8% |
| Capex IntensityCapex / Revenue | 5.4% | 7.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-66.0M | $43.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $136.0M | $23.3M | ||
| Q3 25 | $137.0M | $18.0M | ||
| Q2 25 | $35.0M | $40.2M | ||
| Q1 25 | $-25.0M | $29.4M | ||
| Q4 24 | $22.0M | $19.9M | ||
| Q3 24 | $154.0M | $27.3M | ||
| Q2 24 | $15.0M | $31.6M | ||
| Q1 24 | $41.0M | $19.9M |
| Q4 25 | $60.0M | $8.1M | ||
| Q3 25 | $63.0M | $-1.5M | ||
| Q2 25 | $-54.0M | $23.9M | ||
| Q1 25 | $-135.0M | $13.2M | ||
| Q4 24 | $-70.0M | $2.2M | ||
| Q3 24 | $94.0M | $13.1M | ||
| Q2 24 | $-57.0M | $14.0M | ||
| Q1 24 | $-26.0M | $5.5M |
| Q4 25 | 4.3% | 3.8% | ||
| Q3 25 | 4.9% | -0.7% | ||
| Q2 25 | -4.2% | 11.1% | ||
| Q1 25 | -11.9% | 5.9% | ||
| Q4 24 | -5.5% | 1.1% | ||
| Q3 24 | 7.9% | 6.8% | ||
| Q2 24 | -4.7% | 7.4% | ||
| Q1 24 | -2.4% | 2.7% |
| Q4 25 | 5.4% | 7.1% | ||
| Q3 25 | 5.8% | 8.8% | ||
| Q2 25 | 7.0% | 7.6% | ||
| Q1 25 | 9.7% | 7.2% | ||
| Q4 24 | 7.2% | 9.3% | ||
| Q3 24 | 5.0% | 7.4% | ||
| Q2 24 | 5.9% | 9.4% | ||
| Q1 24 | 6.1% | 7.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 3.06× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 8.46× | ||
| Q4 24 | — | — | ||
| Q3 24 | 38.50× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
WRBY
| Retail | $155.2M | 73% |
| E Commerce | $56.8M | 27% |
